PAPER Harrison FE, Bowman GL, Polidori MC

Ascorbic acid and the brain: rationale for the use against cognitive decline.

Nutrients. 2014 Apr 24;6(4):1752-81. PubMed: 24763117

PAPER Tozlu M, Cankurtaran M, Yavuz BB, Cankurtaran ES, Kutluer I, Erkek BM, Halil M, Ulger Z, Cosgun E, Ariogul S

Functional Disability in Alzheimer Disease: A Validation Study of the Turkish Version of the Disability Assessment for Dementia Scale.

J Geriatr Psychiatry Neurol. 2014 Apr 24; PubMed: 24763071

PAPER Silva D, Guerreiro M, Faria C, Maroco J, Schmand BA, Mendonça AD

Significance of Subjective Memory Complaints in the Clinical Setting.

J Geriatr Psychiatry Neurol. 2014 Apr 24; PubMed: 24763068

PAPER

Upcoming meetings related to Alzheimer's disease.

J Alzheimers Dis. 2014 Jan 1;40(3) PubMed: 24762984

PAPER Sun J, Song F, Wang J, Han G, Bai Z, Xie B, Feng X, Jia J, Duan Y, Lei H

Hidden risk genes with high-order intragenic epistasis in Alzheimer's disease.

J Alzheimers Dis. 2014;41(4):1039-56. PubMed: 24762948

PAPER Hernández-Rodríguez M, Correa-Basurto J, Martínez-Ramos F, Padilla-Martínez II, Benítez-Cardoza CG, Mera-Jiménez E, Rosales-Hernández MC

Design of multi-target compounds as AChE, BACE1, and amyloid-β(1-42) oligomerization inhibitors: in silico and in vitro studies.

J Alzheimers Dis. 2014;41(4):1073-85. PubMed: 24762947

PAPER Xie J, Gabelle A, Dorey A, Garnier-Crussard A, Perret-Liaudet A, Delphin-Combe F, Bathsavanis A, Dauphinot V, Lehmann S, Mercier B, Desestret V, Roullet-Solignac I, Vighetto A, Krolak-Salmon P

Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature.

J Alzheimers Dis. 2014;41(4):1109-16. PubMed: 24762946

PAPER Miyashita A, Wen Y, Kitamura N, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Furukawa K, Arai H, Asada T, Harigaya Y, Ikeda M, Amari M, Hanyu H, Higuchi S, Nishizawa M, Suga M, Kawase Y, Akatsu H, Imagawa M, Hamaguchi T, Yamada M, Morihara T, Takeda M, Takao T, Nakata K, Sasaki K, Watanabe K, Nakashima K, Urakami K, Ooya T, Takahashi M, Yuzuriha T, Serikawa K, Yoshimoto S, Nakagawa R, Saito Y, Hatsuta H, Murayama S, Kakita A, Takahashi H, Yamaguchi H, Akazawa K, Kanazawa I, Ihara Y, Ikeuchi T, Kuwano R

Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population.

J Alzheimers Dis. 2014;41(4):1031-8. PubMed: 24762945

PAPER Blanc F, Philippi N, Cretin B, Kleitz C, Berly L, Jung B, Kremer S, Namer IJ, Sellal F, Jaulhac B, de Seze J

Lyme neuroborreliosis and dementia.

J Alzheimers Dis. 2014;41(4):1087-93. PubMed: 24762944

PAPER Lorenz R, Samnick S, Dillmann U, Schiller M, Ong MF, Faßbender K, Buck A, Spiegel J

Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease.

Acta Neurol Scand. 2014 Sep;130(3):164-71. Epub 2014 Apr 25 PubMed: 24762290

PAPER Ma J, Choi BR, Chung C, Min SS, Jeon WK, Han JS

Chronic brain inflammation causes a reduction in GluN2A and GluN2B subunits of NMDA receptors and an increase in the phosphorylation of mitogen-activated protein kinases in the hippocampus.

Mol Brain. 2014 Apr 24;7:33. PubMed: 24761931

Julian Pei

University of Pennsylvania
Lansdale, United States

Maria Jose Sanchez Artero

Psiquiatria
Guadalajara, Spain

Does PET Tracer Reveal Severity of Parkinson's?

RESEARCH NEWS 2014-04-26 Research News In order to gauge the effectiveness of disease-modifying therapies for Parkinson’s, researchers are looking for a biomarker that measures how far a person’s disease has advanced. In the April 21 JAMA Neurology, scientists led by Kun-Ju Lin a

PAPER Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ

Correlation of Parkinson Disease Severity and 18F-DTBZ Positron Emission Tomography.

JAMA Neurol. 2014 Jun 1;71(6):758-66. PubMed: 24756323